Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Screeners that run automatically... and then email you the results! FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Aveo Pharmaceuticals (AVEO)

Aveo Pharmaceuticals (AVEO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 521,445
  • Shares Outstanding, K 34,763
  • Annual Sales, $ 42,300 K
  • Annual Income, $ -53,340 K
  • 60-Month Beta 1.00
  • Price/Sales 5.49
  • Price/Cash Flow N/A
  • Price/Book 18.00
Trade AVEO with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.84
  • Most Recent Earnings -0.09 on 11/07/22
  • Next Earnings Date 03/13/23
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 1.65%
  • IV Percentile 0%
  • IV Rank N/A
  • IV High 0.00% on N/A
  • IV Low 0.00% on N/A
  • Put/Call Vol Ratio N/A
  • Today's Volume N/A
  • Volume Avg (30-Day) N/A
  • Put/Call OI Ratio N/A
  • Today's Open Interest N/A
  • Open Int (30-Day) N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.04
  • Number of Estimates 2
  • High Estimate 0.01
  • Low Estimate -0.09
  • Prior Year -0.21
  • Growth Rate Est. (year over year) +80.95%

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.90 +0.67%
on 12/20/22
15.00 unch
on 01/19/23
+0.09 (+0.60%)
since 12/19/22
3-Month
14.67 +2.25%
on 10/20/22
15.00 unch
on 01/19/23
+0.27 (+1.83%)
since 10/19/22
52-Week
3.06 +390.20%
on 01/28/22
15.00 unch
on 01/19/23
+11.27 (+302.14%)
since 01/19/22

Most Recent Stories

More News
HCA Healthcare (HCA) Rises 43% in 6 Months: More Room to Run?

HCA Healthcare (HCA) is well-poised for growth due to growing patient volumes, acquisitions and adequate cash-generating abilities.

NVO : 138.09 (+0.40%)
HCA : 254.77 (-0.03%)
AVEO : 15.00 (unch)
LIVN : 55.28 (-0.75%)
GSK Signs Deal to Develop Antibodies for Treating Cancer

GSK (GSK) partners with WuXi Biologics to develop bi- & multi-specific T-cell engaging antibodies. GSK will have an exclusive license to develop and commercialize these candidates.

GSK : 35.30 (-0.11%)
AVEO : 15.00 (unch)
AMRN : 1.8500 (+2.21%)
ALLO : 7.92 (+1.15%)
Moderna (MRNA) to Boost mRNA Portfolio With OriCiro Buyout

Moderna (MRNA) inks an agreement to acquire OriCiro for $85 million. The acquisition is expected to expand and boost Moderna's mRNA manufacturing capabilities.

MRK : 105.38 (-1.39%)
MRNA : 189.35 (-2.01%)
AVEO : 15.00 (unch)
ALLO : 7.92 (+1.15%)
BioMarin's (BMRN) Voxzogo Expanded Label Filing Accepted by EMA

The EMA validates BioMarin's (BMRN) label expansion filing for Voxzogo to treat children under two years with achondroplasia. BMRN submits a filing for using Voxzogo in children under five years.

BMRN : 117.27 (+0.25%)
AVEO : 15.00 (unch)
AMRN : 1.8500 (+2.21%)
ALLO : 7.92 (+1.15%)
The Zacks Analyst Blog Highlights AVEO Pharmaceuticals, Cabaletta Bio, Verona Pharma and Wave Life Sciences

AVEO Pharmaceuticals, Cabaletta Bio, Verona Pharma and Wave Life Sciences are included in this Analyst Blog.

AVEO : 15.00 (unch)
WVE : 4.31 (-3.58%)
VRNA : 22.43 (-1.36%)
CABA : 11.86 (+13.49%)
4 Drug Stocks That More Than Doubled This Year

We present four biotech stocks, AVEO, CABA, VRNA and WVE, which despite the current volatile market, have provided more than twice the returns in 2022.

AVEO : 15.00 (unch)
WVE : 4.31 (-3.58%)
VRNA : 22.43 (-1.36%)
CABA : 11.86 (+13.49%)
Are Medical Stocks Lagging AVEO Pharmaceuticals (AVEO) This Year?

Here is how AVEO Pharmaceuticals (AVEO) and Merit Medical (MMSI) have performed compared to their sector so far this year.

AVEO : 15.00 (unch)
MMSI : 69.94 (+0.60%)
Is Basilea Pharmaceutica (BPMUF) Outperforming Other Medical Stocks This Year?

Here is how Basilea Pharmaceutica AG (BPMUF) and AVEO Pharmaceuticals (AVEO) have performed compared to their sector so far this year.

BPMUF : 52.0000 (+13.04%)
AVEO : 15.00 (unch)
uniQure (QURE) Partner Gets FDA Nod for Hemophilia B Gene Therapy

uniQure (QURE) shares rise after its partner CSL Limited received FDA nod for one-time gene therapy, Hemgenix, for treating adults with Hemophilia B.

AVEO : 15.00 (unch)
QURE : 21.24 (-0.70%)
ETON : 3.59 (-1.37%)
IMCR : 60.69 (+0.03%)
Palisade Bio's (PALI) LB1148 Gets FDA Fast-Track Designation

Palisade Bio (PALI) gets Fast Track status from the FDA for its lead drug, LB1148, for accelerated return of bowel function following gastrointestinal (GI) surgery.

AVEO : 15.00 (unch)
ETON : 3.59 (-1.37%)
IMCR : 60.69 (+0.03%)
PALI : 2.24 (+0.90%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

AVEO Pharmaceuticals, Inc. is a biopharmaceutical company engaged in discovering, developing and commercializing novel cancer therapeutics. Its product candidates are targeted against important mechanisms known or believed to be involved in cancer. Tivozanib, the Company's lead product candidate, is...

See More

Key Turning Points

3rd Resistance Point 15.01
2nd Resistance Point 15.01
1st Resistance Point 15.00
Last Price 15.00
1st Support Level 14.99
2nd Support Level 14.99
3rd Support Level 14.98

See More

52-Week High 15.00
Last Price 15.00
Fibonacci 61.8% 10.44
Fibonacci 50% 9.03
Fibonacci 38.2% 7.62
52-Week Low 3.06

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar